These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 34752208)

  • 1. Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan.
    Tohda Y; Matsumoto H; Miyata M; Taguchi Y; Ueyama M; Joulain F; Arakawa I
    J Asthma; 2022 Nov; 59(11):2162-2173. PubMed ID: 34752208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia.
    Ali A; García E; Torres-Duque CA; Rey D; Botero L; Saenz S; Avila MP; Mazo E; Londoño S
    Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):361-374. PubMed ID: 37994432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective.
    Xu X; Schaefer C; Szende A; Genofre E; Katial R; Chung Y
    J Manag Care Spec Pharm; 2023 Nov; 29(11):1193-1204. PubMed ID: 37796731
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of benralizumab versus mepolizumab and dupilumab in patients with severe uncontrolled eosinophilic asthma in Spain.
    Mareque M; Climente M; Martinez-Moragon E; Padilla A; Oyagüez I; Touron C; Torres C; Martinez A
    J Asthma; 2023 Jun; 60(6):1210-1220. PubMed ID: 36322679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States.
    Sullivan PW; Li Q; Bilir SP; Dang J; Kavati A; Yang M; Rajput Y
    Curr Med Res Opin; 2020 Jan; 36(1):23-32. PubMed ID: 31491337
    [No Abstract]   [Full Text] [Related]  

  • 7. Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations.
    Akenroye A; Marshall J; Simon AL; Hague C; Costa R; Jamal-Allial A; McMahill-Walraven CN; Haffenreffer K; Han A; Wu AC
    J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1568-1574.e2. PubMed ID: 38431251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matching-adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics.
    Bourdin A; Husereau D; Molinari N; Golam S; Siddiqui MK; Lindner L; Xu X
    Clin Exp Allergy; 2020 Apr; 50(4):442-452. PubMed ID: 31943429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma.
    Bateman ED; Khan AH; Xu Y; Guyot P; Chao J; Kamat S; Rowe P; Burnett H; Msihid J; Weinreich D; Pavord ID
    Respir Med; 2022 Jan; 191():105991. PubMed ID: 35090688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness Analysis of Omalizumab for Severe Allergic Asthma in Japan Using Real-World Evidence.
    Igarashi A; Kaur H; Choubey A; Popli A; Muthukumar M; Yoshisue H; Funakubo M; Ohta K
    Value Health Reg Issues; 2022; 27():41-48. PubMed ID: 34784547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
    Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
    Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world effectiveness of dupilumab versus benralizumab and mepolizumab.
    Bleecker E; Blaiss M; Jacob-Nara J; Huynh L; Guo T; Ye M; Stanford RH; Wang Z; Soler X; Nag A; Nair R; Borsos K
    Allergy Asthma Proc; 2024 Jul; 45(4):219-231. PubMed ID: 38760161
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.
    Basagaña M; Martínez-Rivera C; Padró C; Garcia-Olivé I; Martínez-Colls M; Navarro J; Pardo L; Cruz P; Cardona Peitx G; Carabias L; Roger A; Abad J; Rosell A
    Ann Med; 2024 Dec; 56(1):2317356. PubMed ID: 38364218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma.
    Zafari Z; Sadatsafavi M; Marra CA; Chen W; FitzGerald JM
    PLoS One; 2016; 11(1):e0146003. PubMed ID: 26751790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of benralizumab for severe, uncontrolled oral corticosteroid-dependent asthma in Sweden.
    Andersson M; Janson C; Kristensen T; Szende A; Golam S
    J Med Econ; 2020 Aug; 23(8):877-884. PubMed ID: 32324093
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative Effectiveness of Mepolizumab, Benralizumab, and Dupilumab among Patients with Difficult-to-Control Asthma: A Multicenter Retrospective Propensity-matched Analysis.
    Kearney CM; Sangani R; Shankar D; O'Connor GT; Law AC; Walkey AJ; Bosch NA
    Ann Am Thorac Soc; 2024 Jun; 21(6):866-874. PubMed ID: 38241013
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-utility analysis of dupilumab add on therapy versus standard therapy in adolescents and adults for severe asthma in Colombia.
    Antonio Buendía J; Patiño DG
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):575-580. PubMed ID: 34860616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologics for chronic rhinosinusitis.
    Chong LY; Piromchai P; Sharp S; Snidvongs K; Philpott C; Hopkins C; Burton MJ
    Cochrane Database Syst Rev; 2020 Feb; 2(2):CD013513. PubMed ID: 32102112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation.
    Akenroye AT; Segal JB; Zhou G; Foer D; Li L; Alexander GC; Keet CA; Jackson JW
    J Allergy Clin Immunol; 2023 May; 151(5):1269-1276. PubMed ID: 36740144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.